Anavex Pulls Alzheimer’s Drug Application in Europe After EMA Feedback

Anavex Life Sciences has withdrawn its EU marketing application for blarcamesine as an add-on therapy for early Alzheimer’s. Shares fell sharply after EMA committee feedback.